TNF and Alzheimer disease: A double-blind study in mild and moderate AD patients treated with subcutaneous etanercept (anti-TNF agent) did not show significant changes in cognitive function, behavior, and global functions, though there was a positive trend in the anti-TNF-α treatment group (Butchart et al., 2015).